The Vector Development Group at VecX discovers novel AAV capsids with the potential to improve gene therapies. The group focuses on improving delivery to a target tissue type - including eye, muscle, liver, and CNS. This role requires a broad molecular biology skillset and the ability to perform a variety of assays using standardized protocols. You will learn and apply diverse methods for building libraries of AAVs and characterizing their properties. You will also work to optimize AAV engineering protocols. This is a highly collaborative position in which you will integrate across the many disciplines, including cloning, tissue processing, vector production, and in molecular assays.
- Responsibilities:
Support in executing functional program workflows in:
- library cloning
- viral vector production
- tissue processing and molecular assays
Compose relevant documentation, e.g. process reports, progress updates, and SOPs
Support in optimizing existing methods and implementing new methods based on technical advances in the field
Collect data from standard procedures and experiments and support in data analyses
Train new staff members
Collaborate with colleagues across teams
Assist in lab organization, including ordering supplies, restocking, and sample tracking
Follow lab protocols and safety regulations
- Basic qualifications:
PhD in biology, biochemistry, biomedical engineering, or related fields
2+ years hands-on wet lab experience
Experience in DNA/RNA purification and analysis protocols (qPCR, RT-qPCR, ddPCR, etc.)
Experience in mammalian cell culture and chemical transfections
Experience in standard molecular biology methods such as cloning, gel electrophoresis, and primer design
Ability to follow advanced protocols and procedures
Ability to document and maintain an organized account of lab work and results
- Preferred qualifications:
3+ years of experience in biotech industry
Expertise in at least one of the following areas:
Library cloning
Viral vector production
Tissue processing and molecular assays
Experience with AAV therapeutics